Performance of ENTA Enanta Pharmaceuticals | -54.2% in 12m
Compare ENTA with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Enanta Pharmaceuticals with its related Sector/Index XBI
Performance Duell ENTA vs XBI
| TimeFrame | ENTA | XBI |
|---|---|---|
| 1 Day | -7.12% | -1.52% |
| 1 Week | -6.04% | 1.45% |
| 1 Month | -8.93% | 10.08% |
| 3 Months | -5.16% | -1.30% |
| 6 Months | 35.7% | 24.09% |
| 12 Months | -54.2% | 6.83% |
| YTD | 20.3% | 1.05% |
| Rel. Perf. 1m | -1.88 | |
| Rel. Perf. 3m | 1.03 | |
| Rel. Perf. 6m | 1.09 | |
| Rel. Perf. 12m | -7.62 |
Is Enanta Pharmaceuticals a good stock to buy?
No, based on ValueRay Fundamental Analyses, Enanta Pharmaceuticals (NASDAQ:ENTA) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -83.00 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ENTA as of May 2024 is 11.75. This means that ENTA is currently overvalued and has a potential downside of -3.13% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ENTA as of May 2024 is 11.75. This means that ENTA is currently overvalued and has a potential downside of -3.13% (Sold with Premium).
Is ENTA a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 3
- Sell: 1
- Strong Sell: 0
Values above 0%: ENTA is performing better - Values below 0%: ENTA is underperforming
Compare ENTA with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -7.68% | -15.86% | 18.29% | -82.55% |
| US NASDAQ 100 | QQQ | -8.00% | -17.88% | 19.62% | -89.39% |
| US Dow Jones Industrial 30 | DIA | -7.43% | -14.39% | 20.90% | -76.15% |
| German DAX 40 | DBXD | -5.80% | -14.08% | 18.52% | -68.62% |
| UK FTSE 100 | ISFU | -7.58% | -18.48% | 19.44% | -68.89% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -7.19% | -13.66% | 33.56% | -46.96% |
| Hongkong Hang Seng | HSI | -8.19% | -31.79% | 31.99% | -48.83% |
| Japan Nikkei 225 | EXX7 | -7.10% | -9.81% | 23.90% | -64.97% |
| India NIFTY 50 | INDA | -8.46% | -12.13% | 18.10% | -84.06% |
| Brasil Bovespa | EWZ | -5.95% | -12.22% | 39.44% | -66.95% |
ENTA Enanta Pharmaceuticals vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -7.23% | -12.88% | 18.50% | -90.02% |
| Consumer Discretionary | XLY | -6.51% | -14.20% | 28.89% | -73.07% |
| Consumer Staples | XLP | -7.09% | -13.99% | 21.36% | -60.27% |
| Energy | XLE | -7.51% | -8.92% | 21.72% | -77.60% |
| Financial | XLF | -8.03% | -14.16% | 13.75% | -86.90% |
| Health Care | XLV | -8.03% | -14.23% | 21.37% | -67.49% |
| Industrial | XLI | -6.18% | -12.96% | 16.35% | -81.95% |
| Materials | XLB | -6.44% | -12.52% | 19.86% | -73.84% |
| Real Estate | XLRE | -8.28% | -16.96% | 26.88% | -65.10% |
| Technology | XLK | -8.61% | -18.95% | 21.02% | -89.84% |
| Utilities | XLU | -7.54% | -19.49% | 17.12% | -67.43% |
| Aerospace & Defense | XAR | -7.11% | -17.29% | 21.43% | -78.67% |
| Biotech | XBI | -7.49% | -19.01% | 11.59% | -61.07% |
| Homebuilder | XHB | -6.62% | -15.93% | 5.42% | -105.09% |
| Retail | XRT | -5.56% | -15.62% | 15.58% | -83.74% |
Does Enanta Pharmaceuticals outperform its market, is ENTA a Sector Leader?
No, over the last 12 months Enanta Pharmaceuticals (ENTA) made -54.24%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months ENTA made -5.16%, while XBI made -1.30%.
No, over the last 12 months Enanta Pharmaceuticals (ENTA) made -54.24%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months ENTA made -5.16%, while XBI made -1.30%.
| Period | ENTA | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -8.93% | 10.08% | 6.93% |
| 3 Months | -5.16% | -1.30% | 6.91% |
| 12 Months | -54.24% | 6.83% | 28.31% |